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Summary
Despite evidence demonstrating the role of 1-integrin in the regulation of cancer cell proliferation in vitro, the importance
of this cell adhesion receptor during the initiation and progression of epithelial tumors in vivo remains unclear. Here we
have used the Cre/LoxP1 recombination system to disrupt 1-integrin function in the mammary epithelium of a transgenic
mouse model of human breast cancer. Using this approach, we show that1-integrin expression is critical for the initiation of
mammary tumorigenesis in vivo, and for maintaining the proliferative capacity of late-stage tumor cells. These observations
provide a direct demonstration that 1-integrin plays a critical role in both the initiation and maintenance of mammary
tumor growth in vivo.
Introduction tion of integrin function in 3-dimensional cell culture models of
mammary tumorigenesis (Kenny and Bissell, 2003; Wang et
The oncogenic conversion of a primary epithelial cell to a malig- al., 2002; Weaver et al., 1997). Although integrins have not
nant tumor has been shown to involve multiple genetic events, traditionally been regarded as protooncogenes, there is accu-
including the activation of growth-promoting pathways and the mulating data suggesting that these molecules may play an
inactivation of tumor suppressor genes and gene products (Ha- important cooperative role during tumor induction by activated
nahan and Weinberg, 2000). Evidence is accumulating, how- oncogenes. A potential tumorigenic role for the 1-integrin sub-
ever, that the growth of epithelial tumors also depends on inter- unit, for example, has been attributed to reciprocal signaling
actions between the transformed cells and the stromal between 1-integrin-containing receptors and activated growth
microenvironment, regardless of the underlying genetic lesions factor receptors (Adelsman et al., 1999; Falcioni et al., 1997;
(Bissell et al., 2002; Ronnov-Jessen et al., 1996; Shekhar et al., Moro et al., 1998; Wang et al., 1998). Indeed, reversion of the
2003; Wiseman and Werb, 2002). A growth-promoting role for transformed phenotype by blocking 1-integrin binding activity
in human breast cancer cells was shown to be accompaniedthe extracellular matrix (ECM) may explain the strong stromal
response accompanying the formation of aggressive epithelial by downregulation of EGFR signaling (Wang et al., 2002; Weaver
et al., 1997).tumors (Ronnov-Jessen et al., 1996), as well as the synthesis
of ECM components by individual tumor cells (Saulnier et al., Lateral signaling between activated growth factor receptors
and integrins is associated with a number of distinct integrin-1996).
A critical growth-promoting role for the tumor stroma has associated signaling molecules, including integrin-linked kinase
(ILK), focal adhesion kinase (FAK), and the c-Src family of tyro-been demonstrated experimentally, primarily through the inhibi-
S I G N I F I C A N C E
Crosstalk between integrin receptors and activated growth factor receptors has been hypothesized to play a critical role in the
initiation and progression of human cancer. Here we provide direct demonstration that the 1-integrin adhesion receptor is required
for transformation in vivo by an activated oncogene. The mechanistic explanation for this result suggests that the requirement for
1-integrin signaling pathways may apply to a variety of activated oncogenes known to be involved in human cancers. In addition,
a proliferative block induced by the suppression of FAK phosphorylation in primary tumor cells lacking 1-integrin resembles the
clinical phenomenon of tumor dormancy. These experiments therefore provide a novel model for the therapeutic intervention of
human breast cancer.
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sine kinases (Dedhar et al., 1999; Hanks and Polte, 1997; Howe few tumors arising in these crosses revealed that they still re-
tained a functional 1-integrin allele, revealing selective pres-et al., 1998; Sieg et al., 1999, 2000). In the case of c-Src, the
potent transforming properties of this molecule have been asso- sure for 1-integrin expression during tumorigenesis. In addi-
tion, the deletion of 1-integrin in cultured mammary tumor cellsciated with the phosphorylation and activation of FAK (Gabarra-
Niecko et al., 2003; Xing et al., 1994). After binding to an auto- was found to be associated with a decrease in the phosphoryla-
tion of FAK tyrosine residues, including the c-Src binding site.phosphorylation site on 1-integrin-associated FAK, c-Src
phosphorylates several tyrosine residues along the carboxyl The deletion of 1-integrin from these PyV MT-induced tumor
cells also inhibited the capacity of these cells to proliferate andterminus of the FAK molecule, which subsequently provide bind-
ing sites for molecules such as Grb2. The phosphorylation of form tumors in vivo. Taken together, these observations suggest
that retention of 1-integrin expression is required for onco-FAK has been shown to be important for several aspects of
c-Src signaling, including cell cycle progression and the regula- gene-induced mammary tumorigenesis and mammary tumor
growth in vivo.tion of focal adhesion turnover during cell migration (Oktay et
al., 1999; Webb et al., 2004), as well as playing a critical role
during the induction of oncogenic transformation by constitu- Results
tively activated versions of c-Src (Xing et al., 1994).
Activation and elevated expression of 1-integrin-coupled A conditional 1-integrin allele can be efficiently
excised from the murine mammary epitheliumsignaling effectors have been implicated in the induction of a
wide variety of human cancers, including those of the breast, To determine whether 1-integrin is required for mammary tu-
morigenesis in vivo, we obtained mice carrying a conditionalcolon, prostate, and ovaries (Ahmed et al., 2003; Cance et al.,
2000; Graff et al., 2001; Marotta et al., 2001; Oktay et al., 2003; 1-integrin allele in which the second coding exon, containing
the ATG translational start site of the 1-integrin gene, wasOwens et al., 1995). In addition, the overexpression of 1-integ-
rin-associated molecules such as ILK can result in the induction flanked with LoxP1 recombination sites (1LoxP1) (Figure 1A)
(Graus-Porta et al., 2001). Previously, neural-specific expressionof mammary tumors in experimental mouse models (White et
al., 2001). Despite the demonstrated importance of these 1- of Cre has been shown to result in complete ablation of 1-
integrin protein in this tissue (Feltri et al., 2002; Graus-Porta etintegrin-associated signaling molecules during tumor progres-
sion, however, the role of the 1-integrin molecule itself remains al., 2001). To facilitate excision of the1LoxP1 allele in the epithelial
compartment of the mouse mammary gland, we bred the condi-unresolved. Unfortunately, addressing the role of the 1-integrin
subunit in tumorigenesis and postnatal development has been tional 1-integrin strain with a separate transgenic strain ex-
pressing Cre in the mammary epithelium (MMTV/Cre) (Figureprecluded primarily by the embryonic lethality resulting from
germline ablation of the 1-integrin gene in mice (Fassler and 1B) (Andrechek et al., 2000). Targeted excision of the 1LoxP1
allele in the mammary glands of 1LoxP1/LoxP1 MMTV/Cre mice wasMeyer, 1995). The recent development of mice bearing a condi-
tional allele of the1-integrin gene, however, now enables inves- confirmed using a combination of molecular and immunofluo-
rescent approaches. As shown in Figure 1C, targeted recombi-tigators to circumvent this limitation, facilitating the analysis of
1-integrin function in tissues of the postnatal mouse (Graus- nation of the 1LoxP1 allele could be demonstrated by PCR analy-
sis of mammary gland DNA from 1LoxP1/LoxP1 MMTV/Cre animals,Porta et al., 2001).
Given the potential importance of 1-integrin in mammary using primers which amplify both the intact and Cre-deleted
forms of the 1LoxP1 allele (Feltri et al., 2002; Graus-Porta et al.,tumorigenesis, we have used this conditional 1-integrin allele
to generate a mammary-specific knockout of 1-integrin in a 2001). Amplification of the unexcised form of the 1LoxP1 allele
likely reflects the presence of stromal cell DNA in the prepara-mouse model of human breast cancer. To accomplish this, we
introduced the conditional1-integrin allele into transgenic mice tion. A corresponding reduction in total 1-integrin protein in
mammary glands of 1LoxP1/LoxP1 MMTV/Cre mice, relative to con-expressing the polyomavirus (PyV) middle T (MT) oncogene and
the Cre recombinase, both under the transcriptional control of trol FVB mice, was confirmed by immunoblot analysis of mam-
mary epithelial cell lysates (Figure 1D).the mouse mammary tumor virus (MMTV) promoter/enhancer.
The MMTV/PyV MT mammary tumor model affords several im- The specificity of MMTV/Cre-mediated excision of the1LoxP1
allele was demonstrated by immunofluorescence microscopyportant advantages. Firstly, mammary tumors that arise in this
strain appear with complete penetrance, and after a relatively of frozen mammary gland sections, using anti-1-integrin poly-
clonal antisera. Examination of the mammary epithelium derivedshort latency period (Guy et al., 1992). Secondly, tumor progres-
sion in the MMTV/PyV MT strain recapitulates many aspects of from wild-type virgin FVB animals revealed that 1-integrin is
normally expressed along the basolateral surface of the ductalhuman breast cancer progression, providing a model of both
atypical mammary gland hyperplasia as well as papillary and epithelium in the mouse mammary gland (Figure 1E, red stain-
scirrhous carcinomas of humans (Lin et al., 2003; Maglione et ing). In glands prepared from age-matched 1LoxP1/LoxP1 MMTV/
al., 2001). The recapitulation of human breast carcinomas in Cre animals, however, 1-integrin could no longer be detected
this mouse model likely reflects the activation of downstream in many of the sections examined (Figure 1F).
signaling pathways shared by the HER2/neu/erbB2 oncogene,
such as those involving c-Src, Shc, Grb2, PI3K, and the Ras- Ablation of 1-integrin expression does not interfere
with the initial stages of mammary ductal outgrowthMAPK pathway (Ichaso and Dilworth, 2001).
Although ablation of 1-integrin expression from cells of the Prior to the introduction of this conditional 1-integrin allele into
a mouse tumor model, it was necessary to determine whethermouse mammary epithelium did not impair mammary gland
development during puberty, deletion of the conditional 1- targeted ablation of 1-integrin was compatible with normal
mammary gland development. For this purpose, we performedintegrin allele dramatically impaired mammary tumorigenesis in
the MMTV/PyV MT mice. Importantly, molecular analysis of the wholemount analyses of mammary gland development in 4-,
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Figure 2. Targeted ablation of 1-integrin does not impair mammary gland
outgrowth during puberty
Mammary gland whole-mounts were prepared from virgin FVB and
1LoxP1/LoxP1 MMTV/Cre mice at 4 (A and B), 5 (C and D), and 6 (E and F)
weeks of age.
purpose, we bred the 1LoxP1/LoxP1 MMTV/Cre animals to mice
harboring a Cre-responsive -galactosidase reporter construct
(GTRosa26 line) (Figure 3A) (Soriano, 1999). The presence of
the GTRosa 26 allele in MMTV/Cre mice enabled us to moni-
tor at the individual cell level whether a Cre-mediated excisionFigure 1. Targeted ablation of 1-integrin expression in the mouse mammary
event had occurred. When mammary glands from MMTV/Cregland epithelium
GTRosa26 bitransgenic animals were stained in situ with theA and B: LoxP1-flanked 1-integrin (1LoxP1) allele (A) and MMTV/Cre trans-
colorimetric -galactosidase substrate Xgal, sections of the stainedgene (B).
C: PCR analysis of mammary gland DNA from 1LoxP1/LoxP1 MMTV/Cre mice, glands indeed revealed stochastic expression of the MMTV/
confirming Cre-mediated excision of the 1LoxP1 allele. Cre transgene, ranging from 100% to 50% of the luminal epithe-
D: Immunoblot analysis of 1-integrin expression in mammary epithelial cell
lial cells (Figures 3B, 3C, and 3D; blue staining indicateslysates from FVB (lane 1) and 1LoxP1/LoxP1 MMTV/Cre (lane 2) mice.
-galactosidase activity). Visual examination of multiple stainedE: IF analysis of 1-integrin expression (red) in a ductal cross-section from a
12-week-old FVB mouse. DAPI counterstain appears blue. sections subsequently allowed us to estimate the overall propor-
F: IF analysis of 1-integrin expression in a 1LoxP1/LoxP1 MMTV/Cre mouse. Note tion of Cre-expressing cells at approximately 80% (data not
the absence of 1-integrin protein (red), compared to the FVB gland shown
shown).in E.
Given the stochastic nature of MMTV/Cre expression, it was
therefore conceivable that there was preferential retention of
1-integrin-positive cells in the developing glands of 1LoxP1/LoxP1
MMTV/Cre mice. As a result, we prepared wholemounts of5-, and 6-week-old female virgin 1LoxP1/LoxP1 MMTV/Cre animals
mammary glands derived from 12-week-old virgin animals(Figure 2). Examination of glands from these animals indeed
bearing GTRosa26 and MMTV/Cre alleles, and harboring eitherrevealed normal mammary ductal outgrowth during puberty
1 (Figure 3E) or 2 (Figure 3F) copies of the 1LoxP1 allele. These(Figures 2B, 2D, and 2F), indistinguishable from that of control
glands were then stained in situ for Cre-mediated -galac-FVB mice (Figures 2A, 2C, and 2E). In addition, female mice
tosidase activity. The results of this staining protocol revealedharboring this 1LoxP1/LoxP1 MMTV/Cre genetic combination were
that the entire mammary gland tree was positive for -galac-able to lactate and produce viable litters through multiple rounds
tosidase expression in both genotypes (Figures 3E and 3F).of pregnancy (data not shown).
Importantly, higher magnification of mammary ducts from theseSince MMTV promoter activity has been reported to be
Xgal-stained glands indicated that MMTV/Cre-expressing cellsstochastic (unpublished observations), we wanted to confirm
were present in equal proportions between the 2 genotypesthat MMTV/Cre-expressing cells were not at a selective dis-
advantage in the 1LoxP1/LoxP1 MMTV/Cre background. For this (Figures 3G and 3H). In addition, an Xgal-stained section of a
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Figure 3. Mammary epithelial cells contribute to ductal outgrowth in the
absence of 1-integrin expression
A: Cre-responsive GTRosa26 -galactosidase reporter construct present in
the GTRosa26 mouse line.
B–D: Pattern of MMTV/Cre expression (blue) in GTRosa26 MMTV/Cre mice.
E–H: MMTV/Cre expression (blue) in mammary glands of 10-week-old female
GTRosa26 1LoxP1/wt MMTV/Cre (E and G) and GTRosa26 1LoxP1/LoxP1 MMTV/
Cre (F and H) mice. The inset in H shows an Xgal-stained cross-section of a
gland from a lactating GTRosa26 1LoxP1/LoxP1 MMTV/Cre mouse.
Figure 4. Ablation of 1-integrin expression impairs mammary tumorigenesis
mammary gland taken from a lactating GTRosa26 1LoxP1/LoxP1 in MMTV/PyV MT mice
MMTV/Cre animal revealed the presence of a 1-integrin-defi- A and B: 1-integrin expression (brown) in mammary glands from 10-week-
cient differentiated epithelial population expressing the MMTV/ old female MMTV/PyV MT mice. Hyperplastic (black asterisks) and nontrans-
formed (green arrowheads) regions of the epithelium are indicated.Cre transgene (Figure 3H, inset). The presence of these
C and D: Representative mammary gland whole-mounts from 10-week-old-galactosidase-expressing cells in the lactating gland suggests
1LoxP1/wt MMTV/Cre/PyV MT (C) and 1LoxP1/LoxP1 MMTV/Cre/PyV MT (D) mice.
that there was retention of epithelial precursor or stem cell Glands were prepared from 3 littermate pairs. Arrows indicate hyperplastic
populations during development of the glands in GTRosa26 lesions. Average mass of 7 glands for each genotype is included.
E and F: Ratio of hyperplastic lesions (black squares) to total mammary1LoxP1/LoxP1 MMTV/Cre mice, in spite of MMTV/Cre expression.
epithelium surface area (black  red squares), for the 2 representativeTaken together, these observations suggest that 1-integrin
glands shown in the top panels of C and D.expression is not required for the initial stages of mammary
gland development in these mice.
Tumorigenesis in MMTV/PyV MT mice requires (Figures 4A and 4B, green arrowheads), suggesting that there
1-integrin expression may be a correlation between 1-integrin expression and onco-
Immunohistochemical analysis of glands from 10-week-old genic transformation of the epithelium in the MMTV/PyV MT
MMTV/PyV MT mice revealed that 1-integrin is expressed mice.
throughout regions of the mammary epithelium undergoing hy- In order to determine if 1-integrin expression is required
perplastic expansion (Figures 4A and 4B, black asterisks). Ex- for the induction of mammary tumors in these mice, the MMTV/
pression of 1-integrin in these hyperplastic regions was mark- PyV MT transgene was introduced into the 1LoxP1/LoxP1 MMTV/
Cre background. Initial comparison of 2 groups of 7 femaleedly higher than in the adjacent, single-layered epithelium
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virgin mice carrying the MMTV/PyV MT and MMTV/Cre trans- animals. In other words, luminal epithelial cells expressing the
MMTV/Cre transgene would not be expected to undergo PyVgenes, and harboring either 1 (1LoxP1/wt) or 2 (1LoxP1/LoxP1) copies
MT-induced transformation in the 1LoxP1/LoxP1 MMTV/cre/PyV MTof the 1LoxP1 allele, revealed a dramatic difference in the extent
background, due to Cre-mediated excision of both 1LoxP1 al-of mammary tumor development. Like the parental MMTV/PyV
leles. To test this hypothesis, we introduced the GTRosa26MT strain (Guy et al., 1992), palpable mammary tumors could
reporter construct into the 1LoxP1/LoxP1 MMTV/Cre/PyV MT andbe detected as early as 10 weeks in the 1LoxP1/wt MMTV/Cre/
1LoxP1/wt MMTV/Cre/PyV MT mice. This strategy would allow usPyV MT control animals (data not shown). By contrast, mammary
to more accurately follow the fate of individual Cre-expressingtumors were not palpable in 1LoxP1/LoxP1 MMTV/Cre/PyV MT mice
cells during transformation of the mammary gland in these 2at this time point (data not shown). Consistent with these obser-
genetic backgrounds. After obtaining the desired genetic com-vations, whole-mount analysis of mammary glands prepared
binations, mammary glands were removed from 10- and 12-from these 2 groups of 7 animals revealed a dramatic reduction
week-old 1LoxP1/wt MMTV/Cre/PyV MT GTRosa26 control micein the number of hyperplastic mammary lesions in the 1LoxP1/LoxP1
(Figure 5E), as well as from age-matched mice of the 1LoxP1/LoxP1MMTV/Cre/PyV MT background, as compared to the 1LoxP1/wt
MMTV/Cre/PyV MT GTRosa26 background (Figure 5F). TheMMTV/Cre/PyV MT mice (glands from 3 representative 10-
glands were then stained in situ with Xgal and mounted, in orderweek-old littermate pairs are shown in Figures 4C and 4D, with
to visualize the distribution of Cre-expressing cells. Consistenta quantitative comparison shown in Figures 4E and 4F). These
with the results of the RT-PCR analysis (Figure 5D), Cre-express-observations suggest that the mammary-specific deletion of 1-
ing cells in the 1LoxP1/wt MMTV/Cre/PyV MT GTRosa26 controlintegrin can dramatically impair mammary gland transformation
background were present in both the hyperplastic lesions (Fig-and mammary tumor development in the MMTV/PyV MT mice.
ure 5E, black arrow) and normal ductal structures (Figure 5E,After 4 months of age, palpable mammary tumors could be
green arrowhead) of the glands, suggesting that these cellsdetected in the 1LoxP1/LoxP1 MMTV/cre/PyV MT mice. Given the
were not at a selective disadvantage during tumorigenesis. Thestochastic nature of MMTV/Cre expression (Figure 3), we con-
ability of Cre-expressing cells to form tumors in the 1LoxP1/wtsidered the possibility that these tumors were populated by
MMTV/Cre/PyV MT GTRosa26 background is even more appar-cells retaining expression of 1-integrin. Consistent with this
ent by the robust staining seen throughout the gland of ahypothesis, we estimated that approximately 20% of the mam-
tumor-bearing 12-week-old animal (Figure 5E, inset). In themary epithelium of 1LoxP1/LoxP1 MMTV/cre/PyV MT mice has un-
1LoxP1/LoxP1 MMTV/Cre/PyV MT GTRosa26 background, how-dergone transformation by 10 weeks of age (Figure 4F), which
ever, Cre-expressing cells were found to be located exclusivelycoincides with the estimated proportion of Cre-negative cells
within the normal ductal structures (Figure 5F and inset, greenin the glands of GTRosa 26 MMTV/cre mice (Figure 3). As shown
arrowheads). Regions of the glands undergoing hyperplasticby the immunoblot analysis in Figure 5A, 1-integrin protein
proliferation, by contrast, showed no evidence of Cre-mediatedis indeed expressed in late-stage tumors derived from 5- to
-galactosidase activity (Figure 5F and inset, black arrows).6-month-old 1LoxP1/LoxP1 MMTV/cre/PyV MT mice, at levels com-
When tumor sections were prepared from older (16-week-old)parable to those of control MMTV/PyV MT animals (compare
1LoxP1/LoxP1 MMTV/Cre/PyV MT GTRosa26 mice, Xgal staininglanes 1–5 with lanes 6–8). Immunohistochemical analysis of
again confirmed that -galactosidase expression was confinedmultiple sections prepared from these tumors revealed uniform
to morphologically normal ductal structures in the tumors ofexpression of 1-integrin protein throughout the tumor tissue,
these animals (Figure 5G, green arrowheads). The pattern ofindicating that 1-integrin expression was maintained through-
MMTV/Cre expression in Figure 5G is inversely correlated without the entire tumor cell population (a representative section is
the expression of 1-integrin protein in the glands of theshown in Figure 5B). The maintenance of 1-integrin protein
1LoxP1/LoxP1 MMTV/Cre/PyV MT GTRosa26 mice (Figure 5H—
expression in tumors from these 1LoxP1/LoxP1 MMTV/cre/PyV MT
compare 1-integrin expression in hyperplastic regions [black
mice was found to be consistent with the relative lack of excision
arrows] versus single-layered regions of the epithelium [green
of the 1LoxP1 alleles in these tumors, as determined by PCR arrowheads]).
amplification of tumor-derived DNA (Figure 5C, lanes 1–5). The Cre-expressing cells, therefore, appear to be impaired in
1LoxP1 allele, by contrast, was found to be efficiently excised in their ability to undergo hyperplastic proliferation in the1LoxP1/LoxP1
tumors from 1LoxP1/wt MMTV/cre/PyV MT mice, which harbor 1 MMTV/Cre/PyV MT GTRosa26 background. Since the only ge-
copy of the wild-type 1-integrin allele (Figure 5C, lanes 6–8). netic difference between the 1LoxP1/LoxP1 MMTV/Cre/PyV MT
Importantly, the difference in the extent of excision of the 1LoxP1 GTRosa26 and 1LoxP1/wt MMTV/Cre/PyV MT GTRosa26 mice is
allele between the 1LoxP1/LoxP1 MMTV/cre/PyV MT and 1LoxP1/wt 2 versus 1 copy of the 1LoxP1 allele, respectively, these results
MMTV/cre/PyV MT mice was found to correlate with the levels strongly suggest that a functional copy of the 1-integrin gene
of Cre expression in these tumors, as determined by RT-PCR is required for oncogenic transformation of individual epithelial
analysis of tumor-derived RNA (Figure 5D, compare lanes 1–5 cells in the MMTV/PyV MT mice.
with lanes 6–8). These results therefore support the hypothesis
that tumors arising in the 1LoxP1/LoxP1 MMTV/Cre/PyV MT mice Targeted disruption of 1-integrin in PyV MT-induced
are populated by cells retaining expression of 1-integrin, due tumor cells interferes with their capacity
to the absence of MMTV/Cre expression in those cells. to proliferate in vivo and in vitro
The retention of 1-integrin expression in tumors from the Although the above experiments suggest that 1-integrin is
1LoxP1/LoxP1 MMTV/cre/PyV MT mice suggests that there is a required for the initiation of PyV MT-induced mammary tumors
requirement for 1-integrin expression during tumorigenesis. in vivo, it is unclear whether 1-integrin is also required for
This requirement for1-integrin expression would therefore pro- maintenance of the transformed state in late-stage tumors. As
vide selective pressure against MMTV/Cre expression in cells shown by the representative section presented in Figure 6A,
immunohistochemical analysis indeed revealed expression ofundergoing transformation in the 1LoxP1/LoxP1 MMTV/cre/PyV MT
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Figure 5. Cre-expressing cells do not contribute
to tumorigenesis in the 1LoxP1/LoxP1 MMTV/Cre/PyV
MT mice
A: 1-integrin expression is maintained in tumors
of 1LoxP1/LoxP1 MMTV/Cre/PyV MT mice (lanes 1–5).
Tumor lysates from MMTV/PyV MT control mice
were included for comparison (lanes 6–8).
B: 1-integrin (brown) is expressed throughout
1LoxP1/LoxP1 MMTV/Cre/PyV MT-derived tumor tis-
sue. The staining pattern is representative of sev-
eral late-stage tumors.
C: PCR amplification of tumor DNA from
1LoxP1/LoxP1 MMTV/Cre/PyV MT (lanes 1–5) and
1LoxP1/wt MMTV/Cre/PyV MT (lanes 6–8) mice, us-
ing primers which amplify the intact and Cre-
deleted forms of the 1LoxP1 allele, as well as the
wild-type 1-integrin gene. Mammary gland
DNA from a 1LoxP1/wt mouse was amplified as a
reference for PCR fragment size (lane 9).
D: RT-PCR analysis of tumor RNA from 1LoxP1/LoxP1
MMTV/Cre/PyV MT (lanes 1–5), 1LoxP1/wt MMTV/
Cre/PyV MT (lanes 6–8), and 1wt/wt MMTV/Cre/
PyV MT (lane 9) mice, using Cre-specific PCR
primers.
E and F: Xgal-stained mammary gland whole-
mounts from 10-week-old 1LoxP1/wt MMTV/Cre/
PyV MT GTRosa26 (E) and 1LoxP1/LoxP1 MMTV/Cre/
PyV MT GTRosa26 (F) mice. Normal ducts (green
arrowheads) and hyperplastic nodules (black
arrows) are indicated. E is representative of 6
stained glands from 3 mice. F is representative
of 8 stained glands from 4 mice. Insets show
stained glands prepared from older (12-week-
old) animals.
G: Representative section of an Xgal-stained
tumor from a 1LoxP1/LoxP1 MMTV/Cre/PyV MT
GTRosa26 mouse. Normal ductal structures are
indicated by green arrowheads.
H: 1-integrin protein expression (brown) in a
1LoxP1/LoxP1 MMTV/Cre/PyV MT-derived mammary
gland section. Hyperplastic (black arrows) and
nontransformed (green arrowheads) regions are
indicated. This staining pattern is representative
of multiple fields from 3 animals.
1-integrin protein throughout solid, late-stage mammary tu- tumor cells cultured from1LoxP1/LoxP1 MMTV/PyV MT and1LoxP1/wt
MMTV/PyV MT mice (Figure 6C). This strategy involves infectionmors taken from 4- to 5-month-old MMTV/PyV MT mice. Ex-
pression of 1-integrin protein in these tumors was confirmed of the culture monolayers with an adenovirus vector expressing
the Cre recombinase (AdCre). Inclusion of the GTRosa26 re-by immunoblot analysis, as shown in Figure 6B (lanes 1–3). The
levels of 1-integrin expression in PyV MT-induced mammary porter in the donor mice subsequently facilitates identification
of individual cells undergoing Cre-mediated excision. As showntumors were comparable to those induced by expression of an
MMTV/erbB2 (neu) transgene (Figure 6B, lanes 4–6), suggesting by the results of Xgal staining, approximately 30% of the cul-
tured tumor cells can be infected in this way (Figures 6D andthat 1-integin expression may be common to oncogene-
induced mouse mammary tumors (levels of neu protein are 6G). Despite a corresponding reduction in 1-integrin protein
levels, the AdCre-infected 1LoxP1/LoxP1 MMTV/PyV MT GTRosa26shown in the middle panel). The proportion of epithelial cells
in these tumors was normalized by blotting with an antibody culture did not exhibit an increase in apoptotic cell death, com-
pared to AdCre-infected control cultures (data not shown).recognizing the cytokeratin-8 (CK8) luminal epithelial protein
(Figure 6B, bottom panel). The AdCre-infected cultures, from both genotypes, were
subsequently injected into the cleared fat pads of 10 syngeneicIn order to determine if 1-integrin expression is required
for maintenance of the tumor phenotype in MMTV/PyV MT mice, FVB mice (1.5 105 cells/gland). After 3 to 4 weeks, solid tumors
could be palpated at the site of injection in 5 mice of the controlwe developed a strategy to excise the1LoxP1 alleles from primary
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Figure 6. Cells expressing PyV MT are unable to
contribute to tumor growth following loss of 1-
integrin
A: 1-integrin (brown) is expressed throughout
late-stage PyV MT-induced mammary tumors.
This staining pattern is representative of multiple
sections from PyV MT-induced tumors, prepared
after 4 months of age.
B: 1-integrin expression in MMTV/PyV MT-
induced tumors (lanes 1–3), MMTV/erbB2 (neu)-
induced tumors (lanes 4–6), and normal mam-
mary glands (lanes 7 and 8). Levels of erbB2 (neu)
protein are shown in the middle panel. CK8 was
used as a control for protein loading and epithe-
lial cell content.
C: Strategy for excising the 1LoxP1 alleles from
late-stage tumor cells, by infection with an Ad-
Cre vector.
D and G: Tumor cells were cultured from
GTRosa26 1LoxP1/wt MMTV/PyV MT (D) and
GTRosa26 1LoxP1/LoxP1 MMTV/PyV MT (G) mice, in-
fected with AdCre, and stained for Cre-induced
-galactosidase expression 3 days later (gal-
expressing cells appear blue). Eosin counterstain
appears pink.
E, F, H, and I: Cells from D (E and F) and G (H
and I) were injected into the cleared fat pads
of syngeneic FVB mice. Resulting tumors were
stained for -galactosidase expression and sec-
tioned (gal-expressing cells appear blue). Eosin
counterstain appears pink.
group, and 7 mice of the AdCre-infected 1LoxP1/LoxP1 MMTV/PyV eration during growth of the tumor (green arrowheads). These
observations suggest that while tumor cells can survive in theMT GTRosa26 culture. To assess the tumorigenic capacity of
the AdCre-infected cells from either genotype, sections of tu- absence of 1-integrin expression, expression of the 1-integrin
subunit is essential for the proliferative expansion of PyV MT-mor material from both sets of injections were stained for
-galactosidase activity. As expected, tumors derived from the induced tumor cells in vivo.
The impaired proliferative capacity of the AdCre-infectedAdCre-infected 1LoxP1/wt MMTV/PyV MT GTRosa26 control cells
exhibited robust staining for -galactosidase activity, indicating 1LoxP1/LoxP1 MMTV/PyV MT tumor cells could be confirmed
in vitro, by costaining an infected culture with antisera to boththat mammary tumor cells retaining one functional copy of the
1-integrin allele could contribute equally to the tumor mass the Cre recombinase and the Ki67 proliferation marker (Figure
7A). As shown by the immunofluorescent staining pattern inin vivo (Figures 6E and 6F, blue staining). In contrast, very few
-galactosidase-positive cells were detected in animals trans- Figure 7A, expression of Cre and of Ki67 was found to be
mutually exclusive in the AdCre-infected cells. The absoluteplanted with AdCre-infected1LoxP1/LoxP1 MMTV/PyV MT GTRosa26
tumor cells (Figures 6H and 6I, blue cells indicated by green segregation of Cre and Ki67 in these cells was confirmed by
the examination of multiple fields (Figure 7D). Parallel analysis ofarrowheads). The small patches of Cre-expressing cells present
in these tumors, rather, seemed to delineate the site of inocula- AdCre-infected 1LoxP1/wt MMTV/PyV MT control cells, however,
revealed coexpression of Cre and Ki67 in a large proportiontion (Figure 6H, green arrowhead). At higher magnification (Fig-
ure 6I), the Cre-expressing cells could be identified as single, of the AdCre-infected cells (Figures 7B and 7D). Similarly, the
nuclear localization of cyclin D1 was found to be impaired inisolated entities, showing no evidence of having undergone prolif-
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Figure 7. 1LoxP1/LoxP1 MMTV/PyV MT tumor cells in-
fected with AdCre fail to express markers of cell
proliferation
A: 1LoxP1/LoxP1 MMTV/PyV MT tumor cells were in-
fected with AdCre, and stained for Cre (green)
and Ki67 (red) expression. The locations of Cre-
positive cells in the third panel are indicated by
white arrowheads.
B: 1LoxP1/wt MMTV/PyV MT control cells were in-
fected and stained as above. The locations of
Cre-positive cells in the third panel are indicated
by white arrowheads.
C: AdCre-infected 1LoxP1/LoxP1 MMTV/PyV MT tu-
mor cells were stained for Cre (green) and Cyclin
D1 (red) expression. The locations of Cre-positive
cells in the third panel are indicated by white
arrowheads.
D and E: Graphical representation of the results
shown in A–C, following analysis of multiple fields.
AdCre-infected tumor cells from 1LoxP1/LoxP1 MMTV/PyV MT mice c-Src tyrosine kinase (Guy et al., 1994). As a result, we assessed
(Figures 7C and 7E). Functional excision in Cre-expressing cells the state of c-Src phosphorylation in PyV MT tumor cells car-
was confirmed by staining infected MMTV/PyV MT GTRosa26 rying the 1LoxP1 alleles, following infection with the AdCre virus.
cultures with antibodies to the -galactosidase reporter protein Immunofluorescence microscopy of infected cells revealed that
(Figure 7A, second panel, inset). Taken together, the results Cre expression did not impact on either PyV MT expression
of these experiments suggest that 1-integrin expression is (Figure 8A) nor the distribution of tyrosine phosphorylated c-Src
required for the proliferation of PyV MT-induced tumor cells (compare Figures 8B and 8C, white arrowheads). In addition,
both in vivo and in vitro.
immunoblot analysis using phosphospecific antibodies directed
to tyrosine 416 (Y416) of c-Src revealed comparable levels ofExcision of 1-integrin suppresses the tyrosine
c-Src phosphorylation between control and AdCre-infectedphosphorylation of FAK in PyV
cells, in spite of reduced 1-integrin protein levels (Figure 8D).MT-transformed tumor cells
These results suggest that the suppression of proliferation inThe ability of PyV MT to transform mammary epithelial cells has
been shown to be dependent on its capacity to activate the AdCre-infected 1LoxP1/LoxP1 MMTV/PyV MT tumor cells was not
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integrin, where FAK was localized to peripheral focal adhesions
(Figure 8F, white arrowheads), there was almost no FAK protein
detected in the focal contacts of AdCre-infected 1LoxP1/LoxP1
MMTV/PyV MT cells (Figure 8G). Taken together, these observa-
tions argue that ablation of 1-integrin directly affects the tyro-
sine phosphorylation of FAK without disrupting the formation
of focal adhesions. Given that activation of FAK has been impli-
cated in cell cycle progression (Zhao et al., 1998), the altered
tyrosine phosphorylation of FAK may account for the block in
cell proliferation that occurs as a result of targeted inactivation
of 1-integrin.
In order to confirm in vivo that the phosphorylation of FAK
is important for tumorigenesis in 1LoxP1/LoxP1 MMTV/Cre/PyV MT
mice, we performed immunohistochemistry on sections of
glands from these animals, using antibodies specific for phos-
photyrosine 397 of FAK (Figure 8I). Positive staining for phos-
phorylated FAK was clearly visible in regions of the glands un-
dergoing hyperplastic proliferation (Figure 8I, black arrows),
whereas phospho-FAK could not be detected in nontrans-
formed regions of the epithelium (Figure 8I, green arrowhead).
Since the distribution of phospho-FAK was found to overlap
Figure 8. Ablation of 1-integrin expression suppresses FAK phosphorylation with the expression of 1-integrin in the glands of 1LoxP1/LoxP1
in PyV MT-induced tumor cells MMTV/Cre/PyV MT mice (compare with Figure 5H), these results
A: Cre (green) and PyV MT (red) expression in AdCre-infected 1LoxP1/LoxP1 argue that 1-integrin-mediated FAK phosphorylation may be
MMTV/PyV MT-derived tumor cells. necessary for PyV MT-induced mammary tumorigenesis in vivo.B and C: Distribution of phospho-c-Src (Y416) (red) in uninfected (B) and
AdCre-infected (C) 1LoxP1/LoxP1 MMTV/PyV MT-derived tumor cells.
D: Phosphorylation status of c-Src (Y416) in Adgal-infected (lane 1) and Discussion
AdCre-infected (lane 2) 1LoxP1/LoxP1 MMTV/PyV MT-derived tumor cells.
E: Focal distribution of paxillin (red) in AdCre-infected 1LoxP1/LoxP1 MMTV/PyV 1-integrin is dispensable for the initial stages
MT-derived tumor cells.
of mammary ductal outgrowthF and G: Distribution of FAK (red) in uninfected (F) and AdCre-infected (G)
There is an increasing body of evidence implicating members1LoxP1/LoxP1 MMTV/PyV MT-derived tumor cells.
H: Immunoblot analysis of Adgal-infected (lane 1) and AdCre-infected of the integrin family as important signaling components in-
(lane 2) 1LoxP1/LoxP1 MMTV/PyV MT-derived tumor cells, using antibodies for volved in promoting the malignant growth of tumor cells (Wang
1-integrin (top panel), phospho-FAK (Y576), phospho-FAK (Y397), and FAK. et al., 2002). Here, we demonstrate that the functional integrity ofI: Distribution of phospho-FAK (Y397) (brown) in a mammary gland section
1-integrin is absolutely required for the induction of mammaryfrom a 12-week-old 1LoxP1/LoxP1 MMTV/Cre/PyV MT mouse. Hyperplastic
(black arrows) and nontransformed (green arrowhead) regions of the epi- tumors in a well-characterized transgenic mouse model of hu-
thelium are indicated. This staining pattern is representative of multiple fields man breast cancer. We further demonstrate that ablation of 1-
from 3 animals. integrin in mammary tumor cells is associated with a proliferative
block resulting in viable but dormant cancer cells. These obser-
vations provide compelling evidence that 1-integrin plays a
critical role in tumor progression and dormancy.
due to the inability of PyV MT to recruit and activate the c-Src The ablation of 1-integrin expression in the mammary epi-
tyrosine kinase. thelium, however, did not impair the initial stages of mammary
We therefore decided to examine the phosphorylation status gland outgrowth during puberty. In contrast to PyV MT-induced
of FAK, which has been shown to be important for mediating mammary tumors, whole-mount analyses of normal glands har-
the biological effects of both c-Src and 1-integrin (Gabarra- boring the Cre-responsive GTRosa26 reporter construct sug-
Niecko et al., 2003). In response to integrin engagement, FAK gested that 1-integrin-negative mammary epithelial cells were
is phosphorylated at tyrosine residue 576 (Y576) in its kinase not subjected to a selective disadvantage in the mammary epi-
domain, followed by phosphorylation at the c-Src binding site thelium of these mice. The presence of -galactosidase-positive
(Y397) (Kornberg et al., 1992). We therefore examined the phos- cells in the lactating glands of these mice suggests that a 1-
phorylation status of these 2 important tyrosine residues in the integrin-deficient stem cell population was maintained during
FAK molecule following AdCre infection of the1LoxP1/LoxP1 MMTV/ development. These cells, however, seemed to be at a prolifera-
PyV MT tumor cells, by immunoblotting with phosphospecific tive disadvantage following repeated rounds of pregnancy and
antibodies. As shown in Figure 8H, phosphorylation of both lactation (data not shown). Consistent with these observations,
Y576 and Y397 on FAK were found to be reduced in AdCre the mammary-specific expression of a dominant-negative allele
infected 1LoxP1/LoxP1 MMTV/PyV MT cells (Figure 8H, lane 2), as of 1-integrin was reported to have no obvious effects on mam-
compared to Adgal-infected cells (Figure 8H, lane 1). Interest- mary gland outgrowth in virgin animals, while resulting in a
ingly, the targeted disruption of 1-integrin did not interfere with growth disadvantage during lactation (Faraldo et al., 1998,
the capacity of cultured MMTV/PyV MT tumor cells to form 2002). It is conceivable that other members of the integrin family
paxillin-containing focal adhesions (Figure 8E, white arrow- are able to functionally compensate for loss of 1-integrin in
the mammary epithelium during development, or that mammaryheads). However, in contrast to cells retaining a functional 1-
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epithelial proliferation during ductal outgrowth is primarily de- Lean et al., 2001). Similar to the selection for retention of 1-
pendent on exogenous hormones such estrogen. integrin expression in mammary tumors of MMTV/PyV MT mice,
the papillomas that arose in FAK/ mice were found to be from
1-integrin is required for mammary tumor cells overexpressing the FAK protein from the remaining allele
progression: Implications for human (McLean et al., 2001). The specific requirement for FAK signaling
breast cancer during mammary tumorigenesis awaits future experimentation.
The targeted disruption of 1-integrin was shown to have a The retention of 1-integrin null tumor cells in tumor cell
profound effect on oncogene-induced mammary tumor devel- transplants suggests that the primary function of 1-integrin is
opment in the MMTV/PyV MT mice. By introducing the to promote cell proliferation. In many respects, the presence of
GTRosa26 -galactosidase reporter construct into the genetic oncogene-induced tumor cells that are unable to proliferate
combination, we have shown that tumors which develop in but still retain viability bears a remarkable resemblance to the
the 1LoxP1/LoxP1 MMTV/Cre/PyV MT background arise from cells phenomenon of tumor dormancy. In this regard, it is interesting
which fail to express the MMTV/Cre transgene, and have there- to note that the inhibition of FAK signaling has been shown to
fore been selected to retain a functional 1-integrin gene. Com- induce dormancy in human carcinoma cells in vivo (Aguirre
bined with the molecular analysis of these tumors, these results
Ghiso, 2002). Similarly, erbB2-induced mammary tumors that
strongly suggest that 1-integrin expression is required for the
emerge from dormancy frequently acquire a spindle cell pheno-initial stages of PyV MT-induced mammary tumorigenesis
type (Moody et al., 2002), which is also characteristic of mam-in vivo.
mary tumors that have been induced by elevated expression ofIt is important to point out that an initial report by Lin et
ILK (White et al., 2001). It is tempting to speculate that integrin-al. (2003), involving immunohistochemical analysis of PyV MT-
coupled pathways, such as those involving ILK or FAK, mayinduced mammary lesions, indicated that 1-integrin expres-
play an important role in the regulation of tumor dormancy.sion was lost during PyV MT-induced transformation. Here,
Whether activation of these pathways is involved in emergencehowever, we clearly show by both immunohistochemical and
of tumors from dormancy will require further studies.immunoblotting techniques that 1-integrin protein is indeed
The observation that 1-integrin is required for mammaryrobustly expressed throughout multiple samples of late-stage
tumor progression in the MMTV/PyV MT transgenic mousePyV MT-induced mammary tumors. Whether this difference re-
model of human breast cancer has important therapeutic impli-flects antibody choice or sample preparation is not clear, but
cations for the treatment of human breast cancer. Given thatan extensive analysis of both MMTV/PyV MT and MMTV/erbB2
(neu)-induced tumors clearly demonstrates that 1-integrin ex- therapeutic inhibitory antibodies directed against 1-integrin
pression is maintained in these oncogene-induced mouse mam- have already been shown to be effective in reverting the tumori-
mary tumors. In addition, the expression of 1-integrin protein genic phenotype of breast cancer cell lines (Wang et al., 2002;
in mammary tumors induced by overexpression of ILK (unpub- Weaver et al., 1997), it is conceivable that such therapeutic
lished data) suggests that 1-integrin may be important for agents may be ideally suited for the treatment of primary breast
tumor induction by a variety of oncogenes. cancers. Other potential therapeutic targets for blocking tumor
The ablation of 1-integrin expression in established PyV development include integrin-coupled signaling pathways such
MT-induced tumor cells results in inhibition of the proliferative as those involving ILK and FAK. In this regard, it has recently
capacity of these cells, both in vivo and in vitro. These observa- been demonstrated that pharmacological inhibition of ILK can
tions are consistent with those of previous studies involving interfere with prostate tumor growth by inhibition of tumor angio-
the phenotypic reversion of malignant cells by inhibition of 1-
genesis (Tan et al., 2004). The future development of therapeutic
integrin binding activity (Wang et al., 2002; Weaver et al., 1997).
reagents against 1-integrin and its coupled signaling pathwaysIn both examples, reversion of the tumorigenic phenotype was
has excellent potential as an effective therapy to block cancerassociated with a block in cell proliferation, rather than induction
growth and recurrence.of apoptotic fate (Wang et al., 2002; Weaver et al., 1997). Inter-
estingly, engagement of the 1-integrin-associated ILK has
Experimental proceduresbeen shown to be important in promoting cell cycle progression
through upregulation of cyclin D1 expression in various cell Animals
types, both in vitro and in vivo (D’Amico et al., 2000; Radeva MMTV/PyV MT, 1LoxP1, MMTV/Cre, and GTRosa26 mice were generated
et al., 1997; Terpstra et al., 2003; Troussard et al., 2003). Future and characterized as described elsewhere (Andrechek et al., 2000; Graus-
studies involving the conditional inactivation of ILK in mouse Porta et al., 2001; Guy et al., 1992; Soriano, 1999). The animals were housed
mammary tumor models should allow us to elucidate the relative in the Central Animal Facility at McMaster University, under compliance with
the Animal Research Ethics Board (AREB). All animals were in the FVBcontribution of this 1-integrin-associated kinase to mammary
genetic background.tumor progression in vivo.
In addition to ILK, the activation of FAK following 1-integrin
Antibodiesengagement has been shown to be critical for promoting entry
Primary antibodies used in these experiments include anti-1-integrin rabbitinto the cell cycle (Oktay et al., 1999; Zhao et al., 1998). Consis-
polyclonal (M-106) (Santa Cruz), anti-CK-8 (NCL-CK8-TS1) (Novocastra),tent with these observations, we have observed a decrease in
anti-Cre mAb (MMS-106A), and rabbit polyclonal (PRB-106C) (Covance),
the tyrosine phosphorylation status of FAK following ablation
anti-Ki67 mAb (MM1) (Novocastra), anti-cyclin D1 mAb (72-13G) (Santa
of 1-integrin expression in PyV MT-induced tumor cells. A Cruz), anti-PyV MT mAb (Pab 762) (gift of Dr. Steven Dilworth), anti-FAK,
critical role for FAK during tumor progression has been noted anti-pFAK (Y576), anti-pFAK (Y397) rabbit polyclonals (Upstate), anti-c-Src
in other tumor models, such as during the induction of papilloma mAb (GD11) (Upstate), and anti-pSrc (PyV416) polyclonal (Cell Signaling
Technology).formation during experimental mouse skin carcinogenesis (Mc-
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Glands were processed overnight in acetone, and stained in Harris’ hematox- References
ylin (Fisher Scientific) for several hours (Webster et al., 1998). After dehydra-
tion in xylenes, glands were mounted using Permount (Fisher Scientific).
Adelsman, M.A., McCarthy, J.B., and Shimizu, Y. (1999). Stimulation of 1-
integrin function by epidermal growth factor and heregulin- has distinct
IHC and IF analysis of tissue sections requirements for erbB2 but a similar dependence on phosphoinositide 3-OH
For paraffin-embedded tissue, samples were first deparaffinized in 3 changes kinase. Mol. Biol. Cell 10, 2861–2878.
of xylenes. Sections were heated in 10 mM sodium citrate (pH 6), followed
Aguirre Ghiso, J.A. (2002). Inhibition of FAK signaling activated by urokinaseby incubation in 3% H2O2 for 20 min. Samples were incubated in primary receptor induces dormancy in human carcinoma cells in vivo. Oncogene
antibody (1:100) for 1 hr at RT, washed in PBS, and incubated in FITC- or
21, 2513–2524.
Cy3-labeled (Molecular Probes) (IF) or HRP-conjugated (Jackson Immunore-
Ahmed, N., Riley, C., Oliva, K., Stutt, E., Rice, G.E., and Quinn, M.A. (2003).search Laboratories) (IHC) secondary antibody (1:1000) for 30 min at RT.
Integrin-linked kinase expression increases with ovarian tumour grade and
is sustained by peritoneal tumour fluid. J. Pathol. 201, 229–237.In situ -galactosidase assay
Glands were spread on 35 mm culture dishes and fixed for 1 hr in 2% PFA Andrechek, E.R., Hardy, W.R., Siegel, P.M., Rudnicki, M.A., Cardiff, R.D.,
containing 0.25% glutaraldehyde and 0.01% NP-40. The glands were then and Muller, W.J. (2000). Amplification of the neu/erbB-2 oncogene in a
rinsed in PBS and incubated in the Xgal staining solution (1 PBS, 2 mM mouse model of mammary tumorigenesis. Proc. Natl. Acad. Sci. USA 97,
3444–3449.MgCl2, 0.01% sodium deoxycholate, 0.02% NP-40, 30 mM K3FeCN6, 30
mM K4FeCN6, 1 mg/ml Xgal) overnight at RT. For sectioning, tumors and Bissell, M.J., Radisky, D.C., Rizki, A., Weaver, V.M., and Petersen, O.W.
glands were stained as above then embedded in paraffin. Sections were (2002). The organizing principle: Microenvironmental influences in the normal
counterstained with eosin for clear delineation of -galactosidase-express- and malignant breast. Differentiation 70, 537–546.
ing cells.
Cance, W.G., Harris, J.E., Iacocca, M.V., Roche, E., Yang, X., Chang, J.,
Simkins, S., and Xu, L. (2000). Immunohistochemical analyses of focal adhe-Tumor cell explants and adenovirus infection
sion kinase expression in benign and malignant human breast and colon
Excised tumors were finely chopped and incubated in 2 mg/ml collagenase
tissues: Correlation with preinvasive and invasive phenotypes. Clin. Cancer
B (Roche) for 1.5 hr at 37C, with constant agitation. Tumor cell aggregates Res. 6, 2417–2423.
were then washed in DMEM (with spins at 800 rpm) and plated in 10% FBS/
D’Amico, M., Hulit, J., Amanatullah, D.F., Zafonte, B.T., Albanese, C., Bou-DMEM. Cells were infected with Ad vector (gift of Dr. Frank Graham) at 50
zahzah, B., Fu, M., Augenlicht, L.H., Donehower, L.A., Takemaru, K., etmoi for 30 min in PBS/. Analysis for -galactosidase expression, Cre-
al. (2000). The integrin-linked kinase regulates the cyclin D1 gene throughmediated excision events, and protein phosphorylation was performed at 3
glycogen synthase kinase 3 and cAMP-responsive element-binding pro-to 5 days postinfection.
tein-dependent pathways. J. Biol. Chem. 275, 32649–32657.
Dedhar, S., Williams, B., and Hannigan, G. (1999). Integrin-linked kinaseTumor cell transplants
(ILK): A regulator of integrin and growth-factor signalling. Trends Cell Biol.Surgeries were performed in accordance with AREB guidelines. The #4
9, 319–323.glands of anaesthatized, 3-week-old female FVB mice were surgically ex-
posed under sterile conditions. Cells suspended in 10 l sterile PBS were Falcioni, R., Antonini, A., Nistico, P., Di Stefano, S., Crescenzi, M., Natali,
injected into the fat pad using a Hamilton syringe and 255/8 gauge needle, P.G., and Sacchi, A. (1997). 64 and 61 integrins associate with ErbB-2
at a site proximal to the abdominal wall and distal to the nipple. The entire in human carcinoma cell lines. Exp. Cell Res. 236, 76–85.
first quadrant of the fat pad, containing the lymph node and nipple, was
Faraldo, M.M., Deugnier, M.A., Lukashev, M., Thiery, J.P., and Glukhova,then removed by cauterization. Mice were sutured and allowed to recover
M.A. (1998). Perturbation of 1-integrin function alters the development of
under supervision. murine mammary gland. EMBO J. 17, 2139–2147.
Faraldo, M.M., Deugnier, M.A., Tlouzeau, S., Thiery, J.P., and Glukhova,IF microscopy of cultured cells
M.A. (2002). Perturbation of 1-integrin function in involuting mammary glandCells were fixed with 2% PFA for 20 min, and permeabilized with 0.5%
results in premature dedifferentiation of secretory epithelial cells. Mol. Biol.Triton X-100 for 10 min at RT. Primary antibodies (1:100) were diluted in
Cell 13, 3521–3531.
blocking buffer (0.2% Triton X-100, 0.05% Tween-20, 3% BSA in PBS), and
applied to cells for 1 hr at RT. Cells were washed in PBS and incubated Fassler, R., and Meyer, M. (1995). Consequences of lack of 1 integrin gene
expression in mice. Genes Dev. 9, 1896–1908.with FITC- or Cy3-labeled secondary antibodies (Molecular Probes) (1:1000
in blocking buffer) for 30 min at RT. Cells were counterstained with DAPI, Feltri, M.L., Graus Porta, D., Previtali, S.C., Nodari, A., Migliavacca, B.,
and photographed on a Zeiss 510 confocal microscope. Cassetti, A., Littlewood-Evans, A., Reichardt, L.F., Messing, A., Quattrini, A.,
et al. (2002). Conditional disruption of 1 integrin in Schwann cells impedes
Acknowledgments interactions with axons. J. Cell Biol. 156, 199–209.
Gabarra-Niecko, V., Schaller, M.D., and Dunty, J.M. (2003). FAK regulatesWe wish to thank Dr. Mina J. Bissell for useful discussions regarding this
biological processes important for the pathogenesis of cancer. Cancer Me-
work. We would also like to thank Dr. Frank Graham and Dr. Steven Dilworth,
tastasis Rev. 22, 359–374.
for supplying the adenovirus vectors and anti-PyV MT antibody, respectively.
Graff, J.R., Deddens, J.A., Konicek, B.W., Colligan, B.M., Hurst, B.M., Carter,This research was funded by grants from the National Institutes of Health
H.W., and Carter, J.H. (2001). Integrin-linked kinase expression increases(W.J.M.), the Canadian Institutes of Health Research (J.A.H.), and the Cana-
with prostate tumor grade. Clin. Cancer Res. 7, 1987–1991.dian Breast Cancer Research Alliance (W.J.M., J.A.H.). D.E.W. and N.A.K.
were supported by predoctoral research scholarships from the US Depart- Graus-Porta, D., Blaess, S., Senften, M., Littlewood-Evans, A., Damsky, C.,
ment of Defense Breast Cancer Research Initiative (DAMD17-99-1-9284 and Huang, Z., Orban, P., Klein, R., Schittny, J.C., and Muller, U. (2001). 1-
DAMD17-02-1-048, respectively). W.J.M. is the recipient of a CRC chair in class integrins regulate the development of laminae and folia in the cerebral
and cerebellar cortex. Neuron 31, 367–379.molecular oncology, McGill University.
CANCER CELL : AUGUST 2004 169
A R T I C L E
Guy, C.T., Cardiff, R.D., and Muller, W.J. (1992). Induction of mammary changes involved in conversion of normal to malignant breast: Importance
of the stromal reaction. Physiol. Rev. 76, 69–125.tumors by expression of polyomavirus middle T oncogene: A transgenic
mouse model for metastatic disease. Mol. Cell. Biol. 12, 954–961.
Saulnier, R., Bhardwaj, B., Klassen, J., Leopold, D., Rahimi, N., Tremblay,
E., Mosher, D., and Elliott, B. (1996). Fibronectin fibrils and growth factorsGuy, C.T., Muthuswamy, S.K., Cardiff, R.D., Soriano, P., and Muller, W.J.
stimulate anchorage-independent growth of a murine mammary carcinoma.(1994). Activation of the c-Src tyrosine kinase is required for the induction
Exp. Cell Res. 222, 360–369.of mammary tumors in transgenic mice. Genes Dev. 8, 23–32.
Shekhar, M.P., Pauley, R., and Heppner, G. (2003). Host microenvironmentHanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100,
in breast cancer development: Extracellular matrix-stromal cell contribution57–70.
to neoplastic phenotype of epithelial cells in the breast. Breast Cancer Res.
Hanks, S.K., and Polte, T.R. (1997). Signaling through focal adhesion kinase. 5, 130–135.
Bioessays 19, 137–145.
Sieg, D.J., Hauck, C.R., and Schlaepfer, D.D. (1999). Required role of focal
adhesion kinase (FAK) for integrin-stimulated cell migration. J. Cell Sci. 112,Howe, A., Aplin, A.E., Alahari, S.K., and Juliano, R.L. (1998). Integrin signaling
2677–2691.and cell growth control. Curr. Opin. Cell Biol. 10, 220–231.
Sieg, D.J., Hauck, C.R., Ilic, D., Klingbeil, C.K., Schaefer, E., Damsky, C.H.,Ichaso, N., and Dilworth, S.M. (2001). Cell transformation by the middle
and Schlaepfer, D.D. (2000). FAK integrates growth-factor and integrin sig-T-antigen of polyoma virus. Oncogene 20, 7908–7916.
nals to promote cell migration. Nat. Cell Biol. 2, 249–256.
Kenny, P.A., and Bissell, M.J. (2003). Tumor reversion: Correction of malig-
Soriano, P. (1999). Generalized lacZ expression with the ROSA26 Cre re-nant behavior by microenvironmental cues. Int. J. Cancer 107, 688–695.
porter strain. Nat. Genet. 21, 70–71.
Kornberg, L., Earp, H.S., Parsons, J.T., Schaller, M., and Juliano, R.L. (1992).
Tan, C., Cruet-Hennequart, S., Troussard, A., Fazli, L., Costello, P., Sutton,Cell adhesion or integrin clustering increases phosphorylation of a focal
K., Wheeler, J., Gleave, M., Sanghera, J., and Dedhar, S. (2004). Regulation
adhesion-associated tyrosine kinase. J. Biol. Chem. 267, 23439–23442. of tumor angiogenesis by integrin-linked kinase (ILK). Cancer Cell 5, 79–90.
Lin, E.Y., Jones, J.G., Li, P., Zhu, L., Whitney, K.D., Muller, W.J., and Pollard, Terpstra, L., Prud’homme, J., Arabian, A., Takeda, S., Karsenty, G., Dedhar,
J.W. (2003). Progression to malignancy in the polyoma middle T oncoprotein S., and St-Arnaud, R. (2003). Reduced chondrocyte proliferation and chon-
mouse breast cancer model provides a reliable model for human diseases. drodysplasia in mice lacking the integrin-linked kinase in chondrocytes. J.
Am. J. Pathol. 163, 2113–2126. Cell Biol. 162, 139–148.
Maglione, J.E., Moghanaki, D., Young, L.J., Manner, C.K., Ellies, L.G., Jo- Troussard, A.A., Mawji, N.M., Ong, C., Mui, A., St.-Arnaud, R., and Dedhar,
seph, S.O., Nicholson, B., Cardiff, R.D., and MacLeod, C.L. (2001). Trans- S. (2003). Conditional knock-out of integrin-linked kinase demonstrates an
genic polyoma middle-T mice model premalignant mammary disease. Can- essential role in protein kinase B/Akt activation. J. Biol. Chem. 278, 22374–
22378.cer Res. 61, 8298–8305.
Wang, F., Weaver, V.M., Petersen, O.W., Larabell, C.A., Dedhar, S., Briand,Marotta, A., Tan, C., Gray, V., Malik, S., Gallinger, S., Sanghera, J., Dupuis,
P., Lupu, R., and Bissell, M.J. (1998). Reciprocal interactions between 1-B., Owen, D., Dedhar, S., and Salh, B. (2001). Dysregulation of integrin-
integrin and epidermal growth factor receptor in three-dimensional basementlinked kinase (ILK) signaling in colonic polyposis. Oncogene 20, 6250–6257.
membrane breast cultures: A different perspective in epithelial biology. Proc.
McLean, G.W., Brown, K., Arbuckle, M.I., Wyke, A.W., Pikkarainen, T., Ruos- Natl. Acad. Sci. USA 95, 14821–14826.
lahti, E., and Frame, M.C. (2001). Decreased focal adhesion kinase sup-
Wang, F., Hansen, R.K., Radisky, D., Yoneda, T., Barcellos-Hoff, M.H., Pet-presses papilloma formation during experimental mouse skin carcinogene-
ersen, O.W., Turley, E.A., and Bissell, M.J. (2002). Phenotypic reversion orsis. Cancer Res. 61, 8385–8389.
death of cancer cells by altering signaling pathways in three-dimensional
contexts. J. Natl. Cancer Inst. 94, 1494–1503.Moody, S.E., Sarkisian, C.J., Hahn, K.T., Gunther, E.J., Pickup, S., Dugan,
K.D., Innocent, N., Cardiff, R.D., Schnall, M.D., and Chodosh, L.A. (2002). Weaver, V.M., Petersen, O.W., Wang, F., Larabell, C.A., Briand, P., Damsky,
Conditional activation of Neu in the mammary epithelium of transgenic mice C., and Bissell, M.J. (1997). Reversion of the malignant phenotype of human
results in reversible pulmonary metastasis. Cancer Cell 2, 451–461. breast cells in three-dimensional culture and in vivo by integrin blocking
antibodies. J. Cell Biol. 137, 231–245.Moro, L., Venturino, M., Bozzo, C., Silengo, L., Altruda, F., Beguinot, L.,
Tarone, G., and Defilippi, P. (1998). Integrins induce activation of EGF recep- Webb, D.J., Donais, K., Whitmore, L.A., Thomas, S.M., Turner, C.E., Parsons,
tor: Role in MAP kinase induction and adhesion-dependent cell survival. J.T., and Horwitz, A.F. (2004). FAK-Src signalling through paxillin, ERK and
EMBO J. 17, 6622–6632. MLCK regulates adhesion disassembly. Nat. Cell Biol. 6, 154–161.
Webster, M.A., Hutchinson, J.N., Rauh, M.J., Muthuswamy, S.K., Anton, M.,Oktay, M., Wary, K.K., Dans, M., Birge, R.B., and Giancotti, F.G. (1999).
Tortorice, C.G., Cardiff, R.D., Graham, F.L., Hassell, J.A., and Muller, W.J.Integrin-mediated activation of focal adhesion kinase is required for signaling
(1998). Requirement for both Shc and phosphatidylinositol 3 kinase signal-to Jun NH2-terminal kinase and progression through the G1 phase of the
ing pathways in polyomavirus middle T-mediated mammary tumorigenesis.cell cycle. J. Cell Biol. 145, 1461–1469.
Mol. Cell. Biol. 18, 2344–2359.
Oktay, M.H., Oktay, K., Hamele-Bena, D., Buyuk, A., and Koss, L.G. (2003).
White, D.E., Cardiff, R.D., Dedhar, S., and Muller, W.J. (2001). MammaryFocal adhesion kinase as a marker of malignant phenotype in breast and
epithelial-specific expression of the integrin-linked kinase (ILK) results in thecervical carcinomas. Hum. Pathol. 34, 240–245.
induction of mammary gland hyperplasias and tumors in transgenic mice.
Oncogene 20, 7064–7072.Owens, L.V., Xu, L., Craven, R.J., Dent, G.A., Weiner, T.M., Kornberg, L.,
Liu, E.T., and Cance, W.G. (1995). Overexpression of the focal adhesion Wiseman, B.S., and Werb, Z. (2002). Stromal effects on mammary gland
kinase (p125FAK) in invasive human tumors. Cancer Res. 55, 2752–2755. development and breast cancer. Science 296, 1046–1049.
Radeva, G., Petrocelli, T., Behrend, E., Leung-Hagesteijn, C., Filmus, J., Xing, Z., Chen, H.C., Nowlen, J.K., Taylor, S.J., Shalloway, D., and Guan, J.L.
Slingerland, J., and Dedhar, S. (1997). Overexpression of the integrin-linked (1994). Direct interaction of v-Src with the focal adhesion kinase mediated by
kinase promotes anchorage-independent cell cycle progression. J. Biol. the Src SH2 domain. Mol. Biol. Cell 5, 413–421.
Chem. 272, 13937–13944.
Zhao, J.H., Reiske, H., and Guan, J.L. (1998). Regulation of the cell cycle
by focal adhesion kinase. J. Cell Biol. 143, 1997–2008.Ronnov-Jessen, L., Petersen, O.W., and Bissell, M.J. (1996). Cellular
170 CANCER CELL : AUGUST 2004
